Dr Parren speaks about advances in the field of T cell engaging bispecifics. Recent advances in bispecific antibody production and clinic successes have resulted in increased interest, but several disadvantages remain when targeting via CD3, the most common approach. CD3 is present on all T cells which means there is poor specificity and activity, and also toxicity.
At Lava Therapeutics, Paul and his colleagues are targeting A specific effector T-cell subset via the γδT cell (gamma delta T cell) marker Vδ2. These γδT cells are a homogeneous population of pro-inflammatory effector T cells that are able to recognize and attack tumour cells with increased efficacy and safety. previously it has been shown that the high presence of these γδT cells in tumors correlates with increased survival.
Lava Therapeutics’ first product will enter the clinic at the end of next year.
The Chain: Protein Engineering Podcast